U.S. Asthma Drugs Market Size, Share, and Trends 2024 to 2034

The U.S. asthma drugs market size is calculated at USD 9.25 billion in 2025 and is forecasted to reach around USD 14.36 billion by 2034, accelerating at a CAGR of 5.03% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : January 2025
  • Report Code : 3757
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Asthma Drugs Market 

5.1. COVID-19 Landscape: U.S. Asthma Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Asthma Drugs Market, By Medication

8.1. U.S. Asthma Drugs Market Revenue and Volume, by Medication

8.1.1. Quick Relief Medications

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Long-term Control Medications

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. U.S. Asthma Drugs Market, By Mode of Administration

9.1. U.S. Asthma Drugs Market Revenue and Volume, by Mode of Administration

9.1.1. Tablets and Capsules

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Liquids

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Inhalers

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Injections

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Sprays and Powders

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. U.S. Asthma Drugs Market, By Source 

10.1. U.S. Asthma Drugs Market Revenue and Volume, by Source

10.1.1. Environmental

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Generic

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. U.S. Asthma Drugs Market, By Organization Type

11.1. U.S. Asthma Drugs Market Revenue and Volume, by Organization Type

11.1.1. Public

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Private

11.1.2.1. Market Revenue and Volume Forecast

Chapter 12. U.S. Asthma Drugs Market, By Application

12.1. U.S. Asthma Drugs Market Revenue and Volume, by Application

12.1.1. Pediatric

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Adults

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Adolescent

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. U.S. Asthma Drugs Market and Trend Forecast

13.1. U.S.

13.1.1. Market Revenue and Volume Forecast, by Medication

13.1.2. Market Revenue and Volume Forecast, by Mode of Administration

13.1.3. Market Revenue and Volume Forecast, by Source

13.1.4. Market Revenue and Volume Forecast, by Organization Type

13.1.5. Market Revenue and Volume Forecast, by Application

Chapter 14. Company Profiles

14.1. Abbott

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Abbott

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Abbott

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Abbott

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Abbott

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Abbott

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Abbott

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Abbott

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Abbott

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Abbott

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The U.S. asthma drugs market size is expected to increase USD 14.36 billion by 2034 from USD 8.79 billion in 2024.

The U.S. asthma drugs market will register growth rate of 5.03% between 2025 and 2034.

The major players operating in the U.S. asthma drugs market are GlaxoSmithKline, Pfizer, Vectura Group, Boehringer Ingelheim, Roche, Novartis, Merck, AstraZeneca, Teva Pharmaceutical, and Others.

The driving factors of the U.S. asthma drugs market are the growing prevalence of asthma and government initiatives, growing use of biologics for the treatment of asthma , and the rising prevalence of psychiatric illnesses.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client